6,7,4'-Trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2

Carcinogenesis

Volumn 32, Issue 4, 2011, Pages 629-635

  Lee, Dong Eun ^a,b   Lee, KiWon ^b,c   Jung, Sung Keun ^a,b   Lee, Eun Jung ^b   Hwang, Jung A ^b   Lim, Tae Gyu ^a,c   Kim, Bo Yeon ^d   Bode, Ann M ^a   Lee, Hyong Joo ^b   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Seoul National University   (South Korea)

^c Konkuk University   (South Korea)

^d Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4',6,7 TRIHYDROXYISOFLAVONE; 4,7 DIHYDROXYISOFLAVONE; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; DAIDZEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BINDING; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; CDC2 PROTEIN KINASE; CELL CYCLE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; FEMALE; HCT116 CELLS; HUMANS; ISOFLAVONES; MICE; MICE, NUDE;

EID: 79953724844     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr008     Document Type: Article

References (29)

1. Fahy,B. et al. (1998) Epidemiology and molecular genetics of colorectal cancer. Surg. Oncol., 7, 115-123.
2. Forte,A. et al. (2008) Dietary chemoprevention of colorectal cancer. Ann. Ital. Chir., 79, 261-267.
3. Garay,C.A. et al. (1999) Chemoprevention of colorectal cancer: dietary and pharmacologic approaches. Oncology (Williston Park), 13, 89-97; discussion 97-100, 105.
4. Greenlee,R.T. et al. (2000) Cancer statistics, 2000. CA Cancer J. Clin., 50, 7-33.
5. Toyomura,K. et al. (2002) Soybeans, soy foods, isoflavones and risk of colorectal cancer: a review of experimental and epidemiological data. Asian Pac. J. Cancer Prev., 3, 125-132.
6. Choi,E.J. et al. (2009) Equol induces apoptosis through cytochrome cmediated caspases cascade in human breast cancer MDA-MB-453 cells. Chem. Biol. Interact., 177, 7-11.
7. Lampe,J.W. (2009) Is equol the key to the efficacy of soy foods? Am. J. Clin. Nutr., 89, 1664S-1667S.
8. Kang,N.J. et al. (2007) Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. J. Biol. Chem., 282, 32856-32866.
9. Kulling,S.E. et al. (2000) Oxidative in vitro metabolism of the soy phytoestrogens daidzein and genistein. J. Agric. Food Chem., 48, 4963-4972.
10. Kulling,S.E. et al. (2001) Oxidative metabolism of the soy isoflavones daidzein and genistein in humans in vitro and in vivo. J. Agric. Food Chem., 49, 3024-3033.
11. Kulling,S.E. et al. (2002) Oxidative metabolism and genotoxic potential of major isoflavone phytoestrogens. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 777, 211-218.
12. Nguyen-Ba,G. et al. (1999) Epigenetic events during the process of cell transformation induced by carcinogens (review). Oncol Rep., 6, 925-932.
13. Katrien Vermeulen,D.R.V.B. et al. (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif., 36, 131-149.
14. Malumbres,M. et al. (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer, 9, 153-166.
15. Shapiro,G.I. (2006) Cyclin-dependent kinase pathways targets for cancer treatment. J. Clin. Oncol., 24, 1770-1783.
16. Colburn,N.H. et al. (1981) Dissociation of mitogenesis and late-stage promotion of tumor cell phenotype by phorbol esters: mitogen-resistant variants are sensitive to promotion. Proc. Natl Acad. Sci. USA, 78, 6912-6916.
17. Ahmad,N. et al. (1997) Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J. Natl Cancer Inst., 89, 1881-1886.
18. Drees,M. et al. (1997) Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res., 3, 273-279.
19. Mateos-Aparicio,I. et al. (2008) Soybean, a promising health source. Nutr. Hosp., 23, 305-312.
20. Messina,M.J. et al. (1994) Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr. Cancer, 21, 113-131.
21. Montenegro,M.F. et al. (2009) Isoflavone genistein inhibits the angiotensinconverting enzyme and alters the vascular responses to angiotensin I and bradykinin. Eur. J. Pharmacol., 607, 173-177.
22. Orgaard,A. et al. (2008) The effects of soy isoflavones on obesity. Exp. Biol. Med., 233, 1066-1080.
23. Atkinson,C. et al. (2005) Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp. Biol. Med., 230, 155-170.
24. Lu,L. et al. (1998) Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans. Am. J. Clin. Nutr., 68, 1500S-1504S.
25. Casagrande,F. et al. (2000) p21CIP1 is dispensable for the G2 arrest caused by genistein in human melanoma cells. Exp. Cell Res., 258, 101-108.
26. Carlson,B.A. et al. (1996) Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res., 56, 2973-2978.
27. De Azevedo,W.F. Jr et al. (1996) Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl Acad. Sci. USA, 93, 2735-2740.
28. DePinto,W. et al. (2006) In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol. Cancer Ther., 5, 2644-2658.
29. Squires,M.S. et al. (2009) Biological characterization of AT7519, a smallmolecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol. Cancer Ther., 8, 324-332.